Omniab Inc (OABI) Stock Price, Quote & News

Company Profile

OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 250 7800

Website: www.omniab.com

Address:

5980 Horton Street, Suite 600, EmeryVille, United States

Gemology Aug. 17 at 8:22 PM

$RIOT $ADBE $OABI $MYSZ $NET *

0 · Reply

Gemology Aug. 17 at 7:29 PM

$BYND $EROC $ENVX $OABI $RIOT gem;;;;

1 · Reply

adayxs Aug. 17 at 6:31 PM

$OABI That 3.79 add is looking better.

0 · Reply

DayTradingPredictions Aug. 17 at 6:21 PM

$OABI oabi

0 · Reply

E_Ross Aug. 17 at 5:42 PM

$OABI If this was a Chinese scam bio it would be up probably about 500%.

0 · Reply

E_Ross Aug. 17 at 5:29 PM

$OABI Trash

0 · Reply

Bill_S_Preston_San_Dimas Aug. 17 at 5:20 PM

$OABI back in $3.76

0 · Reply

Wedge_ Aug. 17 at 4:46 PM

$OABI Back in 3.85

0 · Reply

RunnerSignals Aug. 17 at 4:20 PM

$OABI $CLBK $MRK $CRDL $FDMT hit fresh 52-week highs. oabi runs on 23x volume, fdmt +22.1% on 1.5x

0 · Reply

pasu4 Aug. 17 at 3:54 PM

$OABI I’m in!

0 · Reply

OmniAb raises FY26 cash and equivalents view to $49M-$53M vs. $37M-$41M

Aug 17, 2026, 6:06 AM EDT - 11 hours ago

OmniAb Raises 2026 Financial Guidance

2026-08-17T10:05:26.000Z - 11 hours ago

OmniAb announces collaboration and license agreement with Eli Lilly

LLY

Aug 17, 2026, 6:01 AM EDT - 11 hours ago

OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company

Aug 10, 2026, 8:00 AM EDT - 7 days ago

OmniAb Slides: Corporate presentation

2026-08-06T21:06:57.000Z - 11 days ago

OmniAb reports Q2 EPS (5c), consensus (13c)

2026-08-06T21:06:40.000Z - 11 days ago

OmniAb raises FY26 revenue view to $32M-$36M from $28M-$33M

Aug 6, 2026, 4:30 PM EDT - 11 days ago

OmniAb Earnings Call Transcript: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 11 days ago

OmniAb Slides: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 11 days ago

OmniAb Quarterly report: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 11 days ago

OmniAb Earnings release: Q2 2026

Aug 6, 2026, 4:05 PM EDT - 11 days ago

OmniAb Reports Second Quarter 2026 Financial Results and Business Highlights

2026-07-27T11:20:47.000Z - 21 days ago

Veraxa Biotech advances VXA-222 following milestone in OmniAb pact

VRXA

Jul 16, 2026, 8:00 AM EDT - 4 weeks ago

OmniAb to Report Second Quarter 2026 Financial Results on August 6

2026-07-13T12:06:39.000Z - 5 weeks ago

OmniAb names Nwachuku as Chief Operating Officer

TMO

Jul 13, 2026, 8:00 AM EDT - 5 weeks ago

OmniAb Names Amechi Nwachuku Chief Operating Officer

2026-05-07T22:45:24.000Z - 3 months ago

OmniAb reports Q1 EPS (6c), consensus (10c)

2026-05-07T22:45:12.000Z - 3 months ago

OmniAb raises FY26 revenue view to $28M-$33M, consensus $28.0M

May 7, 2026, 4:30 PM EDT - 3 months ago

OmniAb Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

OmniAb Slides: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

OmniAb Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

OmniAb Quarterly report: Q1 2026

May 7, 2026, 4:05 PM EDT - 3 months ago

OmniAb Reports First Quarter 2026 Financial Results and Business Highlights

Apr 29, 2026, 8:00 AM EDT - 3 months ago

OmniAb Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

OmniAb Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 4 months ago

OmniAb to Participate in Three Upcoming Investor Conferences

Apr 21, 2026, 8:00 AM EDT - 4 months ago

OmniAb to Report First Quarter 2026 Financial Results on May 7

Mar 9, 2026, 7:00 AM EDT - 5 months ago

OmniAb Slides: Corporate presentation

Mar 4, 2026, 4:30 PM EST - 5 months ago

OmniAb Earnings Call Transcript: Q4 2025

Mar 4, 2026, 4:30 PM EST - 5 months ago

OmniAb Annual report: Q4 2025

Mar 4, 2026, 4:30 PM EST - 5 months ago

OmniAb Earnings release: Q4 2025

Mar 4, 2026, 4:30 PM EST - 5 months ago

OmniAb Slides: Q4 2025

2026-03-04T21:21:33.000Z - 5 months ago

OmniAb reports Q4 EPS (11c), consensus (9c)

2026-03-04T21:21:03.000Z - 5 months ago

OmniAb sees FY26 revenue $25M-$30M, consensus $32M

Mar 4, 2026, 4:05 PM EST - 5 months ago

OmniAb Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Feb 24, 2026, 8:00 AM EST - 6 months ago

OmniAb to Participate at the Leerink Partners Global Healthcare Conference

Feb 19, 2026, 8:00 AM EST - 6 months ago

OmniAb to Report Fourth Quarter 2025 Financial Results on March 4

Dec 15, 2025, 5:00 PM EST - 8 months ago

OmniAb Transcript: Investor Update

Dec 15, 2025, 5:00 PM EST - 8 months ago

OmniAb Press release: Investor Update

Dec 15, 2025, 5:00 PM EST - 8 months ago

OmniAb Slides: Investor Update

Dec 15, 2025, 4:05 PM EST - 8 months ago

Launch of OmniUltra Expands OmniAb's Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies

2025-12-15T14:55:08.000Z - 8 months ago

OmniAb management to meet virtually with Craig-Hallum

Dec 4, 2025, 4:05 PM EST - 9 months ago

OmniAb to Hold OmniUltra Virtual Investor Event on December 15

2025-11-17T22:30:10.000Z - 9 months ago

OmniAb signs agreement for antibody discovery with new incubated company

BANX

Nov 17, 2025, 5:23 PM EST - 9 months ago

OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global Investors

2025-11-05T14:22:39.000Z - 10 months ago

OmniAb price target lowered to $7 from $10 at Craig-Hallum

Nov 4, 2025, 4:30 PM EST - 10 months ago

OmniAb Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:30 PM EST - 10 months ago

OmniAb Quarterly report: Q3 2025

Nov 4, 2025, 4:30 PM EST - 10 months ago

OmniAb Earnings release: Q3 2025

Nov 4, 2025, 4:30 PM EST - 10 months ago

OmniAb Slides: Q3 2025

2025-11-04T21:20:48.000Z - 10 months ago

OmniAb reports Q3 EPS (14c), consensus (14c)

2025-11-04T21:20:37.000Z - 10 months ago

OmniAb sees FY25 revenue $18M-$22M, consensus $21.7M

Nov 4, 2025, 4:05 PM EST - 10 months ago

OmniAb Reports Third Quarter 2025 Financial Results and Business Highlights

Oct 16, 2025, 8:00 AM EDT - 10 months ago

OmniAb to Participate in Three Investor Conferences in November

Oct 14, 2025, 8:00 AM EDT - 10 months ago

OmniAb to Report Third Quarter 2025 Financial Results on November 4

2025-09-12T20:05:15.000Z - 1 year ago

OmniAb files to sell 21.25M shares of common stock for holders

Sep 12, 2025, 8:00 AM EDT - 1 year ago

OmniAb Registration statement: Registration Filing

Sep 2, 2025, 8:00 AM EDT - 1 year ago

OmniAb to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

2025-08-25T11:10:11.000Z - 1 year ago

OmniAb to sell 21.254M shares at $1.40 in private placement

Aug 25, 2025, 7:00 AM EDT - 1 year ago

OmniAb Announces $30 Million Private Placement

Aug 6, 2025, 4:30 PM EDT - 1 year ago

OmniAb Earnings Call Transcript: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 1 year ago

OmniAb Quarterly report: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 1 year ago

OmniAb Earnings release: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 1 year ago

OmniAb Slides: Q2 2025

2025-08-06T20:28:37.000Z - 1 year ago

OmniAb reports Q2 EPS (15c), consensus (15c)

Aug 6, 2025, 4:05 PM EDT - 1 year ago

OmniAb Reports Second Quarter 2025 Financial Results and Business Highlights

Jul 16, 2025, 8:00 AM EDT - 1 year ago

OmniAb to Report Second Quarter 2025 Financial Results on August 6

May 13, 2025, 4:05 PM EDT - 1 year ago

OmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration® Platform at the 21st Annual PEGS Boston Summit

May 8, 2025, 4:30 PM EDT - 1 year ago

OmniAb Earnings Call Transcript: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

OmniAb Quarterly report: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

OmniAb Earnings release: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

OmniAb Slides: Q1 2025

2025-05-08T20:29:10.000Z - 1 year ago

OmniAb reports Q1 EPS (17c), consensus (17c)

May 8, 2025, 4:06 PM EDT - 1 year ago

OmniAb Reports First Quarter 2025 Financial Results and Business Highlights

May 8, 2025, 4:05 PM EDT - 1 year ago

OmniAb Introduces the xPloration® Partner Access Program

May 5, 2025, 1:00 AM EDT - 1 year ago

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

May 1, 2025, 8:00 AM EDT - 1 year ago

OmniAb to Participate in Five Upcoming Investor Conferences

Apr 29, 2025, 8:00 AM EDT - 1 year ago

OmniAb Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

OmniAb Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

OmniAb Announces Two New Appointments to its Board of Directors

Mar 18, 2025, 4:30 PM EDT - 1 year ago

OmniAb Earnings Call Transcript: Q4 2024

Mar 18, 2025, 4:30 PM EDT - 1 year ago

OmniAb Annual report: Q4 2024

Mar 18, 2025, 4:30 PM EDT - 1 year ago

OmniAb Earnings release: Q4 2024

Mar 18, 2025, 4:30 PM EDT - 1 year ago

OmniAb Slides: Q4 2024

Mar 18, 2025, 4:05 PM EDT - 1 year ago

OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Feb 24, 2025, 8:00 AM EST - 1 year ago

OmniAb to Report Fourth Quarter 2024 Financial Results on March 18

Feb 3, 2025, 4:57 PM EST - 1 year ago

OmniAb to Participate in Two Investor Conferences in March

Jan 31, 2025, 11:09 AM EST - 1 year ago

Kuehn Law Encourages Investors of OmniAb, Inc. to Contact Law Firm

Dec 16, 2024, 4:15 PM EST - 1 year ago

OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering & Therapeutics Conference

Nov 12, 2024, 4:30 PM EST - 1 year ago

OmniAb Earnings Call Transcript: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

OmniAb Quarterly report: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

OmniAb Earnings release: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

OmniAb Slides: Q3 2024

Nov 12, 2024, 4:05 PM EST - 1 year ago

OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights

Oct 30, 2024, 8:00 AM EDT - 1 year ago

OmniAb to Participate in Two Investor Conferences in November

Oct 22, 2024, 8:00 AM EDT - 1 year ago

OmniAb to Report Third Quarter 2024 Financial Results on November 12

Aug 26, 2024, 8:00 AM EDT - 2 years ago

OmniAb to Participate in Two Investor Conferences in September

Aug 8, 2024, 4:30 PM EDT - 2 years ago

OmniAb Earnings Call Transcript: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

OmniAb Quarterly report: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

OmniAb Earnings release: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

OmniAb Slides: Q2 2024

Aug 8, 2024, 4:05 PM EDT - 2 years ago

OmniAb Reports Second Quarter 2024 Financial Results and Business Highlights

Jul 25, 2024, 8:00 AM EDT - 2 years ago

OmniAb to Report Second Quarter 2024 Financial Results on August 8

Jun 5, 2024, 8:00 AM EDT - 2 years ago

OmniAb Transcript: Jefferies Global Healthcare Conference

Jun 3, 2024, 4:05 PM EDT - 2 years ago

OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology

May 20, 2024, 8:05 AM EDT - 2 years ago

OmniAb to Participate in the Jefferies Global Healthcare Conference

May 15, 2024, 4:05 PM EDT - 2 years ago

OmniAb Presents High-Throughput Single B-cell Screening xPloration® Data at the 20th Annual PEGS Boston Summit

May 15, 2024, 11:30 AM EDT - 2 years ago

OmniAb Transcript: RBC Capital Markets 2024 Global Healthcare Conference

May 9, 2024, 4:30 PM EDT - 2 years ago

OmniAb Earnings Call Transcript: Q1 2024

May 9, 2024, 4:30 PM EDT - 2 years ago

OmniAb Quarterly report: Q1 2024

May 9, 2024, 4:30 PM EDT - 2 years ago

OmniAb Earnings release: Q1 2024

May 9, 2024, 4:30 PM EDT - 2 years ago

OmniAb Slides: Q1 2024

May 9, 2024, 4:05 PM EDT - 2 years ago

OmniAb Reports First Quarter 2024 Financial Results and Business Highlights

May 1, 2024, 8:00 AM EDT - 2 years ago

OmniAb to Participate in Five Investor Conferences in May

Apr 26, 2024, 8:00 AM EDT - 2 years ago

OmniAb Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

OmniAb Proxy statement: Proxy Filing

Apr 22, 2024, 8:00 AM EDT - 2 years ago

OmniAb to Report First Quarter 2024 Financial Results on May 9

Apr 15, 2024, 8:31 AM EDT - 2 years ago

Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics

CNTN

Mar 20, 2024, 4:30 PM EDT - 2 years ago

OmniAb Earnings Call Transcript: Q4 2023

Mar 20, 2024, 4:30 PM EDT - 2 years ago

OmniAb Annual report: Q4 2023

Mar 20, 2024, 4:30 PM EDT - 2 years ago

OmniAb Earnings release: Q4 2023

Mar 20, 2024, 4:30 PM EDT - 2 years ago

OmniAb Slides: Q4 2023

Mar 20, 2024, 4:05 PM EDT - 2 years ago

OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Feb 26, 2024, 8:00 AM EST - 2 years ago

OmniAb to Report Fourth Quarter 2023 Financial Results on March 20

Dec 14, 2023, 4:30 PM EST - 2 years ago

OmniAb Presents New Scientific Data on its OmnidAb™ Platform at the 2023 Antibody Engineering & Therapeutics Conference

Dec 8, 2023, 7:00 AM EST - 2 years ago

OmniAb Registration statement: Registration Filing

Nov 9, 2023, 5:55 PM EST - 3 years ago

OmniAb Highlights OmnidAb™ Launch and its Expanding Drug Discovery Platform at Today's Research & Technology Virtual Event

Nov 9, 2023, 11:00 AM EST - 3 years ago

OmniAb Earnings Call Transcript: Q3 2023

Nov 9, 2023, 11:00 AM EST - 3 years ago

OmniAb Quarterly report: Q3 2023

Nov 9, 2023, 11:00 AM EST - 3 years ago

OmniAb Earnings release: Q3 2023

Nov 9, 2023, 11:00 AM EST - 3 years ago

OmniAb Slides: Q3 2023

Nov 9, 2023, 8:00 AM EST - 3 years ago

OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights

Gemology Aug. 17 at 8:22 PM

$RIOT $ADBE $OABI $MYSZ $NET *

0 · Reply

Gemology Aug. 17 at 7:29 PM

$BYND $EROC $ENVX $OABI $RIOT gem;;;;

1 · Reply

adayxs Aug. 17 at 6:31 PM

$OABI That 3.79 add is looking better.

0 · Reply

DayTradingPredictions Aug. 17 at 6:21 PM

$OABI oabi

0 · Reply

E_Ross Aug. 17 at 5:42 PM

$OABI If this was a Chinese scam bio it would be up probably about 500%.

0 · Reply

E_Ross Aug. 17 at 5:29 PM

$OABI Trash

0 · Reply

Bill_S_Preston_San_Dimas Aug. 17 at 5:20 PM

$OABI back in $3.76

0 · Reply

Wedge_ Aug. 17 at 4:46 PM

$OABI Back in 3.85

0 · Reply

RunnerSignals Aug. 17 at 4:20 PM

$OABI $CLBK $MRK $CRDL $FDMT hit fresh 52-week highs. oabi runs on 23x volume, fdmt +22.1% on 1.5x

0 · Reply

pasu4 Aug. 17 at 3:54 PM

$OABI I’m in!

0 · Reply

0331mike Aug. 17 at 3:45 PM

$OABI ok im in at $3.95

0 · Reply

jabroni1111 Aug. 17 at 3:26 PM

$OABI anyone playing $5 calls?

1 · Reply

BigBazza Aug. 17 at 3:08 PM

$OABI maybe another pump before a pull back

0 · Reply

mku Aug. 17 at 3:07 PM

$OABI will it go to 6 today?

0 · Reply

Mrvandepol Aug. 17 at 3:05 PM

$OABI nice rise

0 · Reply

Wedge_ Aug. 17 at 3:01 PM

$OABI Scaling 4.07 a little

0 · Reply

LewisDaKat Aug. 17 at 3:00 PM

$OABI OmniAb Raises 2026 Financial Guidance https://marketwirenews.com/stock/oabi/news/omniab-raises-2026-financial-guidance-6661700655922212.html?utm_source=stocktwits

0 · Reply

LewisDaKat Aug. 17 at 2:30 PM

$OABI OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company https://marketwirenews.com/stock/oabi/news/omniab-announces-global-collaboration-and-license-ag-8029944234067062.html?utm_source=stocktwits

0 · Reply

Wedge_ Aug. 17 at 2:16 PM

$OABI In @ 4.02

0 · Reply

F14TOMCATIIAF Aug. 17 at 2:08 PM

$OABI 6-7 soooooon

0 · Reply

AlertsAndNews Aug. 17 at 2:05 PM

$OABI interesting options here this morning. news with LLY earlier this morning OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company " Eligible To Receive Up to $370M In R&D and Commercial Milestone Payments"

0 · Reply

topstockalerts Aug. 17 at 1:54 PM

$OABI 📈

0 · Reply

Market Cap	489.37M
Revenue (ttm)	18.67M
Net Income (ttm)	-64.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-346.97%
Debt to Equity Ratio	0.00

Volume	18,221,131
Avg Vol	608,652
Day's Range	N/A - N/A
Shares Out	144.78M
Stochastic %K	85%
Beta	0.45
Analysts	Strong Sell
Price Target	$7.33